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CCM2 MOLECULAR SIGNALING PATHWAY 
Arianne Boylan, Gamze Tanriover, Dana Shin, and Murat Gunel. Department of Neurosurgery, Yale 
University, School of Medicine, New Haven, CT. 
Cerebral cavernous malformations (CCM) are a central nervous system vascular malformation 
often responsible for hemorrhagic strokes. Molecular genetic studies have identified three genes 
(CCM1 KRIT1, CCM2 Malcavernin, and CCM3 PDCD10) and four possible loci responsible for 
the pathogenesis of these lesions. CCM1 functions through integrin signaling and regulation of 
RAC1 activity and may be involved in the MAPK and JNK signaling cascades. We hypothesized 
that CCM2 likely functioned through the same pathways and that CCM3 expression is regulated 
by these stress-induced signaling cascades. 
We showed that CCM2 likely functions through the MAPK pathway as the mouse homolog, 
osmosensing scaffold protein for MEKK3 (OSM), has been shown to interact in the p38 mitogen 
activated protein kinase (p38 MAPK) signaling pathway regulated by RAC1. We confirmed that 
CCM1 and CCM2 signal as a complex since co-immunoprecipitation indicates joint expression. 
We also characterized the role of CCM3 in the MAPK pathway by identifying interacting serine 
threonine kinases (STK) and KIAA0826 based on yeast two-hybrid data. This was further 
examined through immunohistochemical analysis showing CCM3 is expressed in a variety of 
human organs especially arterial vascular endothelium in a similar pattern to CCM2. The yeast 
two-hybrid data supports current theories that there is a link between CCM pathogenesis and the 
ERK-MAPK cascade. These findings correlate with previous studies and further elucidate the 
signaling pathways involved in CCM pathogenesis which may in turn be helpful in future 
therapeutic advances. 
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INTRODUCTION 
Stroke is the third leading cause of death and a leading cause of disability in the 
US. The majority of cerebral infarctions are ischemic in nature but hemorrhagic 
infarctions account for 20% of cerebral vascular accidents. The primary risk 
factors for hemorrhagic stroke include hypertension, coagulation disorders and 
cerebral vascular malformations. These factors are implicated in 5-7% of 
intracranial hemorrhages 1. Vascular malformations are described by their size 
and location with the four most common categories being capillary 
telangectasias , cavemous malformations, venous malformations, and 
arteriovenous malformations (AVM)2. 
Clinical Aspects of Cerebral Cavernous Malformations 
Cavernous malformations are the most commonly identified cerebral vascular 
malformation accounting for 8-15% of central nervous system vascular 
malformations2 . An estimated 2 million Americans have CCMs and have a 50-
70% risk of hemorrhage, epilepsy or neurological deficit during their Iifetime4 
Cerebral cavernous malformations (CCM) are found in 0.5% of the general 
population as sporadic (15-33% of patients) or familial (73%) lesions3 . In general, 
sporadic CCMs are single lesions while the autosomal dominant form presents 
with multiple lesions. The sporadic CCM form tends to be asymptomatic, while 
the familial form exhibits both phenotypic and genetic heterogenecitys. 
2 
eeMs are often an incidental finding on MRI appearing as a raspberry-like 
angioma or popcom lesion2 (Fig 1). eeMs are small hemorrhages isolated 
Gunet .. aI. PNAS. 1995: 92(14):6820-6624. GUnel ei aI. PNAS 2002: W(1 6):10677- 10082. 
Fig 1. MAt images with classic popcorn-like appearance 01 cerebral 
cavernous malfOfmations. Arrows point to lesions. 
to the location of the lesion with hemoglobin degradation products such as 
methemoglobin, hemosiderin and ferritin present6 . These lesions are often 
dynamic in nature and the mechanism of grow1h is thought to be due to repeated 
microhemorrhages or recanalization after intraluminal thrombus? Functional MRI 
imaging may become essential in the evaluation of eeM lesions6, B 
Fig 2. Histological images characterized by welt circumscribed clusters of dilated thin-walled vessels 
that are surrounded by a giiotic rim. (A) Surgical specimen (hUp:lfwww.bram-aneurysm.comlcm.hlml) (8 ) 
Intraoperative image of CeM marked by arrow with corresponding histology (0) (Neurosurg Focus 2006 
American Assoctn Neurological Surgeons) (C), (E) Histology of CeM (Mazza el al. Child's Nerv SyS\ (1991 ) 
7:139146) 
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On histology, CCMs are 2-3mm to several centimeters in diameter and appear as 
clusters of well circumscribed , abnormally dilated thin-walled vessels surrounded 
by a gliotic ring (Fig 2). Clusters of sinusoidal vessels are often found outside 
these capsules9. The walls of CCMs lack elastin and smooth muscle cells and 
are lined by a single layer of endothelial cells 10 The pathology develops as the 
vessel walls become distended because they lack elastin, thus slowing blood 
flow through the vascular space3. 
Cavernous malformations are located in the brain, spinal cord, skin , retinal 
vasculature, liver, and kidney. Cerebral cavernous malformations (CCMs) are 
dynamic and change in size over time ranging from 0.1 to 9cm and are usually 
located in the cortex. CCMs are most commonly found in the frontal and temporal 
lobes with 80-90% being supratentorial usually in the deep cerebral white matter, 
corticomedullary junction or basal ganglia. The most common posterior fossa 
sites include the pons and the cerebellar hemispheres 11. 
Cerebral cavernomas bleed at a rate of 0.7-1.1 % per year. There has not been 
significant data correlating CCM size with the risk of bleeding or neurological 
deficits. In approximately 8-44% of patients, CCMs are associated with other 
vascular malformations such as capillary telangiectasias 11 . The presence of more 
than one type of malformation is associated with increased risk of hemorrhage. 
CCM lesions prone to hemorrhage may have two hits , making them biallelic and 
creating two nonfunctional copies of a CCM gene12, 13 . 
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The clinical symptoms of CCM include recurrent headache, intractable seizures 
(40-50%), and hemorrhagic stroke (10-25%) which may lead to neurological 
deficits (20% of patients) without surgical resection of a symptomatic lesion 14, 
Current treatment is resection of the symptomatic lesion and careful monitoring 
of small asymptomatic lesions15, Clinical studies have shown that patient age, 
gender, symptoms, localization and size of the cavemous malformations are 
important factors in determining timing of surgical resection 16, 17, Preoperative 
imaging is necessary to determine the vascularity of the surrounding tissue, 
Cavemous malformations do not respond to conventional radiotherapy or 
radiosurgery and necessitate microsurgical resection 18 , 
Cavemous malformations provide an excellent genetic model for the study of 
familial stroke syndromes, There is significant evidence for autosomal dominant 
inheritance among monozygotic twins, Studies show that 10-20% of Caucasian 
CCM patients have a first degree relative with a cavemoma, A Dutch study 
showed that 10% of monozygotic twins were likely to suffer a fatal stroke as 
opposed to 5% of dizygotic twins 15 , Hispanic-Americans have a higher 
prevalence of CCMs than the average population, suggesting a founder effect17, 
19 , Affected individuals may share a common ancestor in Sorona County, Mexico 
and there are other "Italian-American" and French families who exhibit the similar 
linkages20, 21, The mechanism through which gene mutations produce CCMs is 
not clear. However, suggested models include a two-hit mechanism in which one 
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mutation occurs in somatic cells and one is inherited or two somatic mutations 
may occur1S 
Familial cases are due to mutations in one of three loci: CCM1 on chromosome 
7q21.2 , CCM2 on 7p15-p13, or CCM3 on 3q25.2-q27. These chromosomal 
abnormalities are associated with the genes KRIT1 or Krev1 /Rap1 A interaction 
Irapped 1 (CCM1) , MGC4607 or Malcavernin (CCM2) , and PDCD10 or 
Programmed Cell Death 10 gene (CCM3) . Normal levels of KRIT1 , Malcav, and 
PDCD10 expression are necessary for angiogenesis. The three characterized 
CCM gene mutations are frameshift or nonsense mutations which result in 
premature truncation of protein products . CCM1 mutations are responsible for 
40% of familial cavernous angiomas. CCM2 mutations account for 20% of 
cavernomas. The remaining 40% of CCM patients have lesions associated with 
CCM3, a fourth CCM mutation, or a combination of the above mutations22 . 
Background and Expression of CCM1 
The CCM1 gene KRIT1 was identified using yeast two-hybrid screening looking 
for proteins interacting with the bait Krev1 /Rap1A mutations in Hispanic 
families23 . The majority of Hispanic-American cases and 40% of total familial 
CCM cases are attributable to CCM1 mutations24 However recent evidence 
suggests that external factors in addition to the CCM1 germline mutation may be 
involved in phenotypic manifestation of the CCM pathology25. The fact that KRIT1 
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is expressed in many tissues throughout the body but CCMs are a pathology 
found only in the central nervous system further confirms this theory26. 
Approximately half of symptomatic CCM1 patients hemorrhage in comparison to 
87% of patients with CCM2 or CCM3 familiallesions23. 
CCM1 encodes a 529aa protein with four ankryin domain which interact with 
RAP1A's carboxyterminal region 27. RAP1A was isolated through its interaction 
with DRAS3 which is a Drosophila melangogaster homologue28. Ras signaling is 
thought to participate in angiogenesis as suggested by abnormal vascular 
development in mouse models29.3o and its interaction with B-Raf which , when 
deficient, initiates endothelial apoptosis in mice3o. RAP1A also participates in 
morphogenesis and cell differentiation31. Recent studies have confirmed that 
RAP1 A signal transduction pathway is involved in vasculogenesis or 
angiogenesis which also links CCM1 to this cellular function32. 
KRIT1 contains an ankyrin and FERM domain which implies a link between 
integrins and the actin cytoskeleton3. The interaction between KRIT1 and RAP1A 
supports a loss of function hypothesis for CCM development and a phenotypic 2-
hit model. KRIT1 splice variants expressed early in angiogenesis interact with 
RasGTPases and microtubules. Integrin signaling plays an important role in CCM 
pathophysiolgy suggesting that KRIT1 regulates bidirectional signaling between 
the extracellular matrix and cellular cytoskeleton. 
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KRIT1 may also be involved in the communication between astrocytes and 
endothelial cells. The CCM phenotype is characterized by leaky CNS vessels , a 
fact which is supported by knowledge that GTPase KRIT1 is expressed in 
endothelial cells and localizes to astrocytic foot processes, suggesting a defect in 
blood brain barrier (BBB) formation35 . 
Many signaling pathways have been recognized as potentially important in CCM 
pathogenesis. KRIT1 contains a NPXY domain which binds Integrin Cytoplasmic 
Domain Associated Protein-1 a (ICAP-1 a) , which in tum is a binding partner of ~-
1 integrin36. Examination of the molecular function of at least one KRIT1 splice 
variant indicates expression during early angiogenesis and identified interaction 
with RasGTPases and microtubules. The Krev1 /Rap1 a gene - GTPase Ras 
KRIT1 interacts with ICAP1 which binds ~-1 integrin and Rac1. The longer KRIT1 
splice variant also interacts with Integrin Cytoplasmic Domain Associated 
Protein-1a (ICAP-1a), which is a binding partner of ~-1 integrin. These 
observations implicate integrin signaling in CCM pathophysiology and further 
suggest that KRIT1 could mediate signaling between the extracellular matrix and 
the cellular cytoskeleton24, 3l This supports integrin signaling in CCM 
pathophysiology, implying that KRIT1 mediates signaling between the 
extracellular matrix and cellular cytoskeleton. 
A KRIT1 -/- knock-out mouse model revealed that loss of the gene results in 
dilation of large vessels33 . This deletion led to death in many of the knock-out 
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animals however it has been shown that mice heterozygous for KRIT1 did not 
develop the vascular lesions26. 33 . Knock-out mice died at embryonic day 8.5 from 
closure of the dorsal aorta due to endothelial proliferation34 . KRIT1 may function 
in Notch4-mediated arterial development, regulation of RAC1 activity and integrin 
signaling3 . 
CCM1 exhibits predominately nuclear expression in response to stress and is 
found in the arterial endothelium of mammalian tissues 10. Within the cerebral 
cortex, CCM1 is evident in the arterial endothelium as well as the astrocytic foot 
processes24 . One clinical study found a family with several patients documenting 
a CCM1 vertebral lesion with cutaneous lesions present22 . This is unusual as 
CCMs are predominately a CNS lesion. 
Background and Expression of CCM2 
The CCM2 gene MGC4607 has been correlated with 20% of familial CCM 
cases38 . The murine homologue of CCM2, osmosensing scaffold protein (OSM), 
was identified as an interacting partner of Mitogen-activated protein kinase 3 
(MEKK3) which activates ERK, JNK, and p38 MAPK signaling depending on the 
cell context and stimulus. There are two primary splice variants at 49 kDa and 
84kDa39. 
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CCM2 shares CCM1's expression pattern in mammalian tissues. Previous data 
has shown expression in brain, heart, lung, kidney, liver and spleen. More 
specifically, CCM2 is expressed in the arterial endothelium of the vasculature of 
these organs and is predominately cy1oplasmic4o In the lungs, CCM2 is 
expressed in the capillary lining of the alveolar walls, bronchioles, columnar 
epithelium and epithelial cilia but not in the venous endothelium. Aortic 
endothelium expresses CCM2 as well. The myocardial and pericardial layers of 
the heart exhibit CCM2 expression in the arterial endothelium as well as the 
coronary arteries. Within the liver, CCM2 expression is evident in the hepatic 
artery and bile duct endothelium, as well as in hepatocy1es. CCM2 is expressed 
in the endothelial lining of the blood-thymus barrier and splenic endothelium. 
Renal interconnected glomerular capillaries express CCM2 as well. Within the 
cerebral cortex, CCM2 is expressed in the cy10plasm of the pyramidal neurons 
and glial cells especially in the astrocy1ic foot processes40. 
The MGC4607 gene is responsible for CCM2 lesions. A yeast two-hybrid screen 
of T-cell cDNA library using the CCM2 murine homologue, OSM, as bait 
identified Mitogen-activated protein kinase 3 (MEKK3) as a binding partner. 
MEKK3 activates the ERK, JNK, and p38 MAPK signaling pathways. The 
activation of a specific pathway by MEKK3 is dependent of the cell line and 
stimulus used. Following hyperosmotic shock, OSM induces p38 expression 
through the MAPK signaling pathway as a scaffold protein. 
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CCM2 also interacts with ICAP-1 which interacts with the RhoGTPases and 
~ 1 integrin which are important in cytoskeleton. CCM2 and ICAP1 bound to 
CCM1 via PTB domains may influence the subcellular localization of CCM1 
Further, recent evidence suggests that CCM2 and CCM1 interacts with MEKK3 
in a complex41 . This suggests that CCM1 and CCM2 may interact as a complex 
regulating RAC1 which activates the MAPK cascade. 
Background and Expression of CCM3 
The CCM3 gene PDCD1 0 was discovered through examination of a large 
deletion in a CCM family. The PDCD10 gene expression was found to be up-
regulated in TF-1 premyeloid cell line after growth factor deprivation and a 
fibroblast cell line after induction of apoptosis42, 43. PDCD10 is highly conserved 
in vertebrates and invertebrates43. PDCD10 is upregulated during apoptosis in a 
human premyeloid cell line and may function in regulation of cell proliferation and 
apoptosis3 . Knockdown of the C. e/egans homolog of PDCD1 0 (2KB06) results 
in increased embryonic lethality although the biological functions of PDCD1 0 
have not been fully characterized . Knockdown C.e/egans survivors exhibit a 
shorter and fatter phenotype. 
In contrast to some studies which have shown that up to 50% of CCM1 lesions 
may be asymptomatic, CCM3 lesions are highly symptomatic26. Patients with 
CCM3 lesions present with symptoms at a younger age and exhibit a higher risk 
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of cerebral hemorrhage, especially during childhood44 Several families have 
been identified with this mutation and the cellular function of POC01 0 in relation 
to angiogenesis and cerebral vessel remodeling is still being investigated43 . 
Background and Expression of CCM4 
The remaining 40% of CCM mutations were formerly all associated with CCM3 
mutations, however more recently a fourth locus was identified on chromosome 
3q26.3-27.2 that appears to be unique from CCM3 on 3q25.2-q2722. 45. 46 . The 
proximity of these two loci to one another may make it difficult to link this new 
locus to a novel protein. The K2015 family has a strong link to the POC010 
locus. A recent study has shown a distinct recombination event between 
0353053 and GATAB1 H05 which excludes the POC01 0 gene indicating the 
presence of a fourth mutation46. 
MAPK Pathway and Serine Threonine Kinases 
Although the mechanisms of cerebral angiogenesis are not understood, the 
MAPK and JNK pathways have been implicated in cerebral angiogenesis. The 
molecular mechanism behind CCM pathology has not been identified although 
three transcripts and protein products have been characterized. 
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The MAPK signaling cascade has been shown to be activated by environmental 
stressors such as osmotic changes which can result in various pathologies 
depending upon the organ system involved. In the eye, corneal epithelium 
exposed to hypertonic states results in decreased cell proliferation4l Osmotic 
stress has also been implicated in the activation of the TAK1-JNK pathway which 
is mediated by NF-KB activation4B The GGM proteins have been shown to 
interact with the highly conserved Ras proteins that act as central regulators for 
several pathways in response to stress49 . 
Mitogen activated protein kinase (MAPK) family members are responsible for the 
maintenance of cells. MAPK regulates apoptosis in response to external stress 
signals5o• The MAPK cascades are critical in using extracellular stimuli for 
intracellular signaling. There are three well known MAPK subfamilies, the 
extracellular signal-related kinase (ERK), c-Jun N-terminal kinase (JNK) and the 
p38 mitogen activated protein kinase (MAPK) signaling cascades. ERK signaling 
acts against Rho-kinases to promote endothelial cell survival and sprouting 
during angiogenesis51. RAS-RAF-MEK-ERK signaling is thought to be important 
in tumor angiogenesis or cell proliferation in pathologies such as GGMs52 . JNK 
and p38 MAPK are the primary stress-induced cellular responses best 
documented through osmotic cellular changes. These two pathways are also 
responsible for apoptosis and the removal of dysfunctional cells. NF-KB is an 
activator of cell survival signaling53. Proinflammatory cytokines such as TNF 
activate both NF-KB and the JNK pathways through TAK1 which is a 
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transforming growth factor-~-activated kinase thought to be regulated by osmotic 
stress 54, 5S 
Tumor necrosis factor receptor-associated factors (TRAF) are multifunctional 
signal adaptors which activate kinase cascades such as c-Jun N-terminal kinase, 
p38 mitogen activated protein kinase and the transcription factor NF-KB56 There 
are six identified TRAFs5l The JNK pathway is initiated by mediators such as 
TNF- ex and IL-1 interacting with TRAF-6, TRAFs act as protein scaffolds and link 
the TRAF domain to the IL-1 receptor pathways in order to regulate apoptosis 
and cytokine signaling58 , Serine/threonine kinases are known to regulate the NF-
KB pathway after TNF-ex and IL-1 cytokine activation57, 59 . One study examined 
astrocytes infected with Escherichia coli, which causes inflammation such as 
meningitis or an abscess, Examination of proinflammatory mediators indicated 
that TNF- ex and other participates in the NF-KB pathway may contribute to 
inflammation in the brain55 , Another study found that the NF-KB pathway in 
epithelial and lymphocytic cells was suppressed with adenosine which is an 
endogenous immunomodulator that has anti-inflammatory and 
immunosuppressive properties60 
The six TRAF proteins each have a different role in cellular responses such as 
the activation of apoptosis or promotion of cell survival. TRAF-1 is associated 
with lipid rafts which participate in apoptosis in the traumatized brain and 
neurogenerative diseases6 1, TRAF-2 activates the NF-KB pathway in order to 
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promote cell survival53, 62, 63. TRAF-2 has a splice variant with an extended RING 
finger domain which inhibits this activation as well thus providing its own direct 
feedback64 TRAF-3 also participates in apoptosis65, TRAF-4 expression has 
been shown to be critical to the ontogenesis of the CN8 and PN8 during mouse 
embryogenesis and is expressed intracellularly in the adult hippocampus and 
olfactory bulb which are active in neoneurogenesis66, 6l TRAF-6 mediates 
signaling from the amino-terminal domain of CD40 signaling , TRAF-6 activates 
NF-KB and function independently of the other TRAF family proteins68 Thus 
TRAF-6 directly induces angiogenesis by activating NF-KB and c-Jun N-terminal 
kinase69 It is interesting to note that lipopolysaccharide (LP8) initiates TRAF-6 
mediated endothelial survival70 
There are 28 members of the 8te20 kinase group in humans with homologues in 
drosophila and Caenorhabditis elegans71. The 8te20 kinases respond to osmotic 
stress to initiate signaling cascades72 , The biological function of mammalian 
8te20 kinases (putative yeast mitogen-activated protein kinases kinases kinase 
kinase , or MAP4k) is largely unknown but they are known to be germinal center 
kinases that are involved in mating pathways73, 8te20 kinases are critical to 
regulation of the cell cycle, apoptosis, and stress responses, Recent data 
suggests that 8te20 kinases also participate in cell volume sensing and CI-
transport regulation 74. As upstream activators of the MAPK cascade the 8te20 
family regulates apoptosis, morphogenesis and cytoskeletal rearrangements and 
thus may be implicated in pathophysiology of many human diseases71. 
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Ste20 is a PAK and germinal center kinase (GCK) family member74 . Ste20 is also 
a p21-activated kinase (PAK) family member which is a MAP4K for three yeast 
MAPK cascades. Ste20 group kinases are upstream activators of MAPK which 
serve to regulate transcription. The Ste20 N-terminus noncatalytic domain binds 
to and inactivates its kinase domain. Once GTP Cdc42 binds to the CRIB domain 
of the N-terminus the Ste20 kinase is activated75 . Deletion of the N-terminal 
domain is a dominant gain-of-function allele76 
C. e/egans is a good model for studying the stress activated signaling cascades 
responsible for apoptosis and cell survival. The loss of GLA-3 in results in 
increased apoptosis. GLA-3 has been shown to participate in the MAPK signaling 
pathway by interacting with MPK-1 which is a meiotic regulator. Thus GLA-3 acts 
as a negative regulator of the MAPK pathway. MPK-1 is the C. e/egans homolog 
of the mammalian ERKl2 and serine/threonine kinases and is required for 
germline development. Thus C. e/egans organisms lacking MPK-1 exhibit 
sterility and increased germ cell apoptosisn 
The yeast two-hybrid assay is an effective tool for recognizing protein-protein 
interactions. The mating pathway in the Saccharomyces cerevisiae is one of the 
best understood eukaryotic signal transduction pathways. The mating signal is 
carried from the plasma membrane to the nucleus via G-protein coupled 
receptors and the mitogen-activated protein kinase (MAPK) signaling cascade. 
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The MAPK pathway is regulated by scaffold proteins and the dephosphorylation 
of kinases which control the pathway via negative feedback based on 
concentrations. Once the G-protein is activated, it initiates the MAPK cascade by 
conveying a signal to effectors in the transmembrane scaffold protein Ste5 
(serine/threonine kinase) which activates Ste11 (MAPKKK), Ste7 (MAPKK) , and 
phosphorylates Fus3 (MAPK). MAPK voyages to the nucleus and delivers the 
signal to downstream effectors which arrest the cell cycle in the G1 phase to 
allow for mating. Thus the yeast mating system is itself a model for the MAPK 
cascade and mating yeast strains which hold different proteins allows the 
researcher to determine whether the two proteins interact78 
The Cre/lox system allows for inducible gene targeting for the expression or 
ablation of any gene to any tissue at a defined time in transgenic mice. This 
allows one to build novel chromosomes and further explore mammalian 
development79 . While C.e/egans and yeast provide models for identification of 
mutant genes and protein interactions, the mouse offers a valuable mammalian 
genetic modelBo 
Based on the recent observation that the mouse homolog of CCM2, 
osmosensing scaffold protein for MEKK3 (OSM), participates in the p38 mitogen 
activated protein kinase (p38 MAPK) signaling pathway, it has been 
hypothesized that human CCM molecules might signal through this pathway as 
well. Both CCM1 and CCM2 have been shown to signal through the p38 MAPK 
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as well as the c-Jun NH2-terminal kinase (JNK). Together with the confirmation 
of MAPK involvement in CCM signaling in humans, Ras GTPase activating 
proteins may also playa role in CCM pathogenesis by modulating the MAPK 
signaling cascades through direct association with CCM2. We sought to prove 
this interaction using a yeast two-hybrid assay. The RasGAP proteins identified 
as binding partners of CCM2 are predominantly expressed in the CNS which 
may explain why CCM pathology is restricted to the CNS although the proteins 
are expressed throughout mammalian tissues. 
CCM1 has been shown to regulate ~1 integrin-mediated cell adhesion through 
ICAP1. CCM1 may regulate RAC1 activity through ICAP1 guanine dissociation 
inhibitor activity and CCM2 acts as a scaffold for RAC1 /MEKK3/MKK3 which 
activates p38 through phosphorylation of MAPK. This relationship suggests the 
possibility that CCM1 and CCM2 may act together as a complex3 . There is 
evidence that interaction between CCM1 /CCM2 is prevented by a CCM2 
missense mutation. This supports theories that CCM lesion pathogenesis may be 
linked to the interaction between CCM1 and CCM2 41. 
The aim of this project was to elucidate the relationship between CCM1 and 
CCM2 in the activation of the p38 MAPK signaling cascade and to further 
characterize CCM3 by analyzing expression in extracerebral and cerebral tissues 
in relation to CCM1 and CCM2. The molecular mechanisms underlying CCM 
pathophysiology are largely unknown. We sought to demonstrate that CCM1 
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and CCM2 function as a complex to activate the p38 MAPK and c-Jun NH2-
terminal kinase signaling pathways and that CCM3 may signal through the p38 
MAPK cascade. We also sought to confirm the interaction between CCM3 and 
serine threonine kinase binding partners identified through the yeast two-hybrid 
assay in order to understand the role of CCM3 in the activation of molecular 
pathways responsible for CCM pathology. 
MATERIALS AND METHODS 
In Vitro Cultures 
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Human umbilical vein endothel ial cells (HUEVC) were cultured in M199 media 
supplemented with 20% FBS, 200mmol/mL L-Glutamine, 1% Penstrep 
(Invitrogen) , and endothelial cell grow1h supplement. 
Neuro2A (N2A) cells were cultured in MEM with Earle 's BSS and supplemented 
with 10% FBS, L-glutamine , sodium pyruvate and non-essential amino acids. 
N2A cells were purchased from ATCC 
COS? cells were grown in low glucose OM EM (GIBCO/BRL) with 10% FBS and 
1 % antibiotic-antimycotic. Cells were grown to confluence on 100x 15mm Petri 
dishes and harvested for protein for Western blot analysis and co-
immunoprecipitation. 
Pre-designed and annealed siRNAs (CCM1 10#15655; CCM2 10#33399; CCM3 
10# 19312; Negative Control 10#4611 ) were purchased from Ambio. siRNAs 
were transfected into cells using Oligofectamine (Invitrogen) at a final 
concentration of 100nM in OptiMEM (Invitrogen) per the manufacurer's 
instructions. Following initial transfection, cells were cultured in normal serum 
media for 4 hours and re-transfected with siRNA at 1 OOnM concentration and 




COS? cells were transfected at 90% confluence with 4ug of CCM1, CCM2 cDNA 
in pDEST52 vectors following the lipofectamine 2000 protocol. COS? cells were 
also co-transfected with 2ug of CCM1 and CCM2. Cells were incubated 36 hours 
at 37"C and ceillysates were collected using 1X Igepal CA-630 Co-IP buffer. 
Lysates were precleared with Protein A-Agarose beads (Pierce) and spun down 
at 4000rpm for 4min at 4°C. The supematant was incubated on a nutator 
overnight at 4°C. This product was combined with Protein A-Agarose beads at 
4°C for 1 hour and centrifuged at 4000rpm. The supernatant was washed with 1X 
Co-IP lysis buffer, boiled and fractionated on a SDS-PAGE and transferred. via 
western blot. 
CCM3 Antibody characterization 
A CCM3 specific antibody was synthesized and affinity purified by Zymed 
Laboratories Inc. (San Francisco, CAl. The specificity of CCM3 antibody was 
tested by transfecting COS? cells with an expression vector encoding a CCM3-
GFP fusion protein. Full length CCM3 gene was cloned into pcDNA-DEST53 
plamsid (Invitrogen, Carisbad, CAl and COS? cells were transfected with either 
this construct as the positive control or Lipofectamine (Invitrogen, Carisbad, CAl 
as the negative control. 
The transfected cells were lysed and products fractionated with SDS/PAGE. The 
protein samples were run on 10% Tris-HCL gels (BIO-RAD, Hercules, CAl for 
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fractionation by electrophoresis followed by transfer to PVDF membrane. Blots 
were blocked in 5% nonfat dried milk in PBS with 0.05% Tween 20. Blots were 
then incubated with a 1: 1 000 dilution of primary antibody ovemight at 4°C 
followed by secondary incubation with horseradish perioxidase conjugated 
affinity purified donkey anti-rabbit IgG (Jackson Immunoresearch Laboratories, 
Inc, West Grove, PAl. Protein bands were visualized using electrochemical 
luminescence reagents (Amersham Biosciences, Piscataway, NJ). For peptide 
competition assays , the primary antibody was incubated with twofold molar 
excess of the immunizing peptide prior to the primary incubation . 
Analysis of CCM3 Expression in Mouse Tissue 
In order to analyze CCM3 and CCM2 protein expression in various tissues , 
organs from a CD-1 mouse were homogenized and 15fl9 of the resulting protein 
Iysates were analyzed by Westem blot. Protein concentrations were determined 
using BSA standards and a Bradford Coomassie Protein Assay Kit from Pierce 
(Rockford , II) . Primary antibodies for Westem blots were used at a 1:1000 
dilution. Membranes were treated as stated above. 
Tissue Collection 
Sections of human organ tissue were obtained from the Department of Pathology 
at Yale University School of Medicine (Human Investigations Committee Protocol 
No, 7680). The tissues were fixed ovemight in 4% paraformaldehyde, embedded 
in paraffin , and sectioned 0.5mm thick. 
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Immunohistochemical Analysis 
Sections were incubated for two hours in a 60°C oven to deparaffinize and 
incubated in Xylene for 10 minutes followed by short incubations through an 
alcohol gradient: 100%, 90% and 70%. In order to optimize CCM3 antigen 
exposure, the slides were placed in 1 Ommol/mL citric acid solution and 
microwaved. A hydrophobic barrier was drawn around the tissue with ImmEdge 
Pen (Vector Laboratories, Inc, Burlingame, CAl. Sections were then rinsed with 
1 xPBS, blocked in H20 2 for 20 minutes to minimize nonspecific staining, and 
rinsed again in 1 xPBS. A visualization system kit from Lab Vision Corporation 
(Fremont, CAl was then utilized. The sections were incubated in Ultra V block 
solution for 10 minutes and without rinsing, a drop of primary antibody was 
added. The tissue was stained with the CCM3 antibody customized from Zymed 
and characterized as mentioned above. As a negative control, some sections 
were incubated in CCM1 or CCM2 antibody. After primary incubation the slides 
were washed in PBS and then incubated for 30 minutes with biotinylated goat 
anti-rabbit IgG antibody (Vector Laboratories Inc, Burlingame, CAl. The sections 
were then put through a series of PBS washes and strepdavidin was applied for 
10 minutes followed by further PBS washes. The chromogenic reaction was 
induced with DAB substrate from Vector Laboratories, Inc. The reaction was 
terminated with tap water and the slides were counterstained with hematoxylin. 
The slides were then dehydrated, and mounted permanently and viewed under a 
light microscope. 
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Microarray Screening and Data Anaylsis 
Total RNA from siRNA treated cells were extracted using QIA shredder followed 
by RNeasy kit per manufacturer's instructions (Qiagen). Isolated mRNA was 
processed for hybridization using 3DNA Array 900 kit (Genisphere) and applied 
to Operon OHU21 K chips containing 21,000 70mer oligos. The results were read 
using image analysis software GenePix S.O and imported into GeneSpring 6.2 
, 
(Silicon Genetics, Redwood City, CAl for gene expression data analysis. To 
reduce the effect of outliers, the median values instead of the mean were used to 
calculate both CyS and Cy3 channel intensities. The intensity values were 
calculated by subtracting the local median background value from the median 
foreground value for each spot. LOWESS normalization using 20% of data for 
smoothing was performed to eliminate dye-related artifacts. The ratio of the 
normalized intensity (CyS/Cy3) calculated by GeneSpring was used for 
expression analysis. Genes with average intensity values less than 1000 for both 
channels, or CyS/Cy3 ratio greater than 0.67 but less than 1.S (i.e. less than SO% 
regulated), were excluded in the subsequent statistical analysis. A one-sample t 
test using p-value cutoff O.OS with multiple test correction (Benjamini and 
Hochberg false positive rate) adjustment to the p-value was applied to the 
distribution of natural logs of the ratios for each gene to determine if the gene 
was statistically differentially expressed. 
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Immunofluorescent Staining 
CCM1 full length mouse cDNA sequence was cloned into pEGFP _N3 expression 
vector (Clontech) by inserting between Hindlll(5') and Xhol(3') sites. A full length 
(1828bp) human CCM2 cDNA was cloned into the pOTB? vector from Open 
Biosystems (MHS1011-60266) between the attB1 and attB2 site-specific 
recombinases. A mammalian expression vector containing full-length CCM2 
cDNA in frame with the GFP gene to its N-terminus was then created using the 
Gateway Technology from Invitrogen with the use of an attR-containing 
pcDEST53 vector. The GFP-tagged constructs were transfected into mouse 
neuroblastoma (N2A) cells with Lipofectamine 2000 (Invitrogen) and cultured in 
OPTI-MEME for 24 hours. 
The cells were treated as detailed with 0.2M Sorbitol or 1 Ong/ml TNFa (R&D 
Systems Inc) for 15 minutes at 37"C and fixed in 4% PFA and blocked in 10% 
normal goat serum followed by incubation with primary antibody (p-p38 or pJNK) 
ovemight. Cells were then washed in 1 X PBS and incubated with Alexa Fluor 
555-conjugated rabbit secondary antibody and washed in 1 X PBS before 
mounting with DAPI-containing mounting medium (Vector). The fixed cells were 
visualized using a ZEISS Axioplan microscope and the images captured using 
the Axiovision software program. 
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Yeast Two-hybrid Screening 
The ProQuest yeast two-hybrid system was used for this assay. For the CCM3 
screening, the interaction was confirmed by cloning full length CCM3 cDNA 
sequence into a Clontech pGADT7 bait vector between the Xho and BamH1 
sites. STK24, STK25 and KIAA0826 were cloned into a prey pGBKT7 vector 
between Not1 and Sal1 sites. The pGBKT7 constructs were transformed into 
AH109 yeast and the pGADT7 construct was transformed into Y187. These were 
confirmed via western blot and checked for self activation on appropriate dropout 
plates. The prey and bait were then mated overnight at 37°C. Constructs were 
plated onto -Leu, -Trp, -Ade/LeufTrp, and -His/LeufTrp/Ade drop out plates and 
incubated at 37°C for 3 to 4 days. Clones were selected on plates lacking 
leucine, tryptophan, and histidine in the presence of 50mM 3AT. 2% 5-f1uoorotic 
acid plates were used for negative selection. Mated cultures were confirmed via 
PCR and sent for sequencing to KECK to confirm that successful mating. 
In order to verify the protein interactions isolated by the yeast-two hybrid a 
reversal of prey and bait vectors was done. By cloning 10ng of full-length human 
CCM3 cDNA including 5' and 3' UTRs (Open Biosystem BC002506 MHS1011-
59014) into a pDEST32 yeast expression pGADT7 bait vector (ProQuest yeast 
two-hybrid system-Gateway Technology, Invitrogen) between the attR1 and 
attR2 sites. This was set against a human fetal brain cDNA library (Invitrogen) 
which was inserted into the pEXP-AD502 prey vector between the attB1 and 
atttB2 sites. Clones were selected on plates lacking leucine, tryptophan, and 
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histidine in the presence of 50mM 3AT. For negative selection, 2% 5-fluoorotic 
acid plates were used. For the re-transformation assay, 10ng of CCM3 cDNA 
was co-transformed with 10ng of test DNA in the MaV203 host yeast strain 
(Invitrogen). Full-length CCM3 cDNA sequence was cloned into a Clontech 
pGADT7 "prey" vector. STK24 and STK25 were cloned into a pGBKT7 "bait" 
vector. The STK24 and STK25 plasm ids were transformed into the yeast strain 
AH109 and the CCM3 prey was transformed in Y187 yeast strain. These two 
yeast strains were then mated in a confirmation yeast two hybrid reaction and 
plated on plates lacking leucine, tryptophan and histidine. For negative selection , 
combination plates were used lacking all three amino acids. 
For the CCM2 yeast two-hybrid analysis the Proquest yeast two-hybrid system 
with Gateway technology was purchased from Invitrogen. The bait was a full 
length CCM2 cDNA sequence (IMAGE biosystems) including 5' and 3' UTRs was 
cloned into pDEST32 between attR1 and attR2 sites. A human fetal brain cDNA 
library (Invitrogen) was inserted into the pEXP-AD502 vector between the attB 1 
and attB2 sites. These clones were selected on plates lacking -His/-Leu/-Trp/-
Ura in the presence of 50mM 3AT. A 0.2% 5Fluoorotic acid plate was used for 
negative selection. CCM2-AD was used as a negative control for the selection 
plate due to co-transformation of full length CCM2-DB with an empty vector 
containing GAL4AD domain. For the retransformation assay, 1 Ong of CCM2 
cDNA was co-transformed with 10ng of test DNA in Ma V203 host yeast strain 
(Invitrogen). 
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PCR of CCM3 and STK24, STK25 and KIAA0826 
Yeast colonies were picked and grown up in YPD broth overnight and presence 
of the desired construct was tested by digesting the construct. The CCM3 
constructs in the pGADT7 vector were digested with BamH1 and Xho1 while the 
STK24, STK25 and KIAA constructs in the pGBKT7 vector were digested with 
NOT1 and SAL 1 overnight at 60' . These products were run out on a 1 % agarose 
gel and to check for bands at 1 .2bp for STK24 and STK25 and 1 .3bp for 
KIAA0826. These bands were excised from the gel and purified using gateway 
technology gel extraction and the KIAA0826, STK24 and STK25 yeast colonies 
were amplified using BDAdvantage enzyme in a 50ul reaction with matched 
primers and using KIAA0826 primers with sal1-tag forward 
(CCGGTCGACTACCAGAGCCTCTAGCTCCTGA) and not-tag reverse 
(CGGGCGGCCGCGTTTCTTTCCTAAAGGCCTGA), STK24 primers with sal1-
tag forward (ccggtcgactgatggctcactccccggtgcagt) and not-tag reverse 
(CGGGCGGCCGCCAAATGCCAAAGGAATTTCA) and STK25 primers with 
sal1-tag forward (gcgccgtcgactagctcacctccggggattt) and not-tag reverse 
(GGCGCGGCCGCTTCCGTCCCCTATCTGAACA). CCM3 primers used bam-
tag forward (ccgggatccGGATGACAATGGAAGAGATGAA) and xho-tag reverse 
(CGGCTCGAGCTTTCAGGCCACAGTTTTGA). Product was run out on 2% 
agarose gel with 100 base pair ladder. These products were sent to KECK for 
sequencing. 
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Gamze Tanriover and Arianne Boylan were both responsible for the 
immunohistochemical data. Dana Shin performed the CCM2 yeast two-hybrid 




Recent studies have shown that CCM1 and CCM2 activate p38 MAPK and JNK 
signaling pathways due to cellular and environmental stressors. We sought to 
confirm that CCM1 and CCM2 act as a complex to initiate p38 MAPK signaling 
through a co-immunoprecipitation. In order to address the role of CCM3 in the 
MAPK signaling and JNK cascades we used the yeast-two hybrid system to 
isolate proteins interacting with CCM3. 
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Fig 3. Coimmunoprecipitation with CCM1 and CCM2 transfecled in COS? cells indicates that the 
proteins are endogenously expressed In this cell line and express as a construct. GFP and FLAG 
antibodies were used as conlrols as GFP is endogenously expressed. CCM1 produces the 
expected band at 62kOa and CCM2 at 49KOa. The GFP bands were expected to be 75kDa. Blot 
A represents CCM1 primary antibody with an antirabbit secondary. Blot B represents CCM2 
primary antibody wilh antirabbit secondary. Blot C represents antiGFP primary anlibody wilh 
anlimouse secondary. . 
CCM1 and CCM2 act as a complex in initiating p38MAPK cascade 
The interaction between CCM1 and CCM2 was analyzed through a co-
immunoprecipitation between the two proteins. COS? cells were transfected with 
CCM1, CCM2 or co-transfected with both and exposed to either a CCM1 
antibody, CCM2 antibody, or to no antibody. CCM constructs tagged with gfp and 
FLAG were used as controls in order to determine if the proteins were 
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endogenously expressed in this cell line (Fig 3). The COS? cells incubated with 
CCM1 primary and anti-rabbit secondary antibodies produced the expected 
results. Under these conditions, COS? cells transfected with CCM 1 and pulled 
down with CCM2 antibody produced a band at 49kDa. Cells which were 
transfected with CCM1, CCM2, the CCM1/CCM2 co-transfection, or non-
transfected cells were pulled down with gfp antibody did not produce a band. 
Cells transfected with CCM2 and pulled down with CCM1 antibody produced the 
expected band at 62kDa. 
Non-transfected cells pulled down with CCM1 produced a band at 62kDa and 
nonctransfected cells pulled down with CCM2 produced a band at 49kDa. Similar 
results were found for Iysates which were incubated in a CCM2 primary and anti-
rabbit secondary antibody. Lysates were incubated in an anti-gfp primary and 
anti-mouse secondary as a control. Only those cells which were pulled down with 
gfp produced a band at the expected band width of ?5kDa (Fig 3). The Iysates 
which were incubated with the anti-gfp and anti-mouse antibodies produce a 
band corresponding to gfp and not CCMl or CCM2 showing that the co-
immunoprecipitation accurately reflects interaction between the CCM protein and 
antibody. 
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CCM1 and CCM2 are involved in p38MAPK and JNK signaling 
Microarray analysis of HUVEC cells after CCM1 and CCM2 knockdown indicated 
that CCM1 and CCM2 but not CCM3 are involved in the p38 MAPK and JNK 
signaling cascades. CCM1 and CCM2 silencing affected expression of several 
genes which have been associated with these stress-responsive signaling 
pathways. However, CCM3 knockdown did not affect the genes. This implies that 
CCM3 does not activate these signaling cascades (Table 1) . 
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Table I. Genes in the MAPK sir-oilling pnthwaJ$ aIT«ttd by CCM I and ca.U silencing. 
Table above ibus\ratas the effects of CCM1 and CCM2 on p38 MAPK as well as JNK signalng pathways (Shin, D. 
unpublished data). 
CCM2 interacts with RasGAP proteins 
GTPase Ras and other small proteins in this family are upstream signaling 
molecules which regulate the MAPK signaling cascadeB1 . CCM1 was initially 
cloned as a binding partner of a small GTPase Ras-related protein (Rap1A) in a 
yeast two-hybrid assayB2. Thus CCM1 and CCM2 might regulate MAPK signaling 
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via Ras molecules. A yeast two-hybrid assay using CCM2 as bait against a 
human fetal brain library, isolated three Ras GTPase activating proteins 
(RasGap) (Fig 5a). Of 37 independent clones, 11 were Synaptic GAP (SynGAP) , 
four were Ras activating protein like-2 (RASAL2) and two were ASK1 interacting 
protein 1 (AIP1 or DAB21 P) . The CCM2 yeast two-hybrid screen indicated that 
CCM2 interacts with KIF5A (Fig 5) . 
a 
b 
Fig 5. Identification of RasGAP protens as CCM2 binding partners. (a) Yeast two-hybrid screening 
identified SYNGAP; AASAL2 as potential interactors with GCM2. Control E confers a strong 
interaction phenotype,CCM2-AD is a negative control for the selection plate due to co-
transformation of full length CCM2-0B with an empty vector containing GAL4AD domain. (b) 
Assessment of their interaction by (e-transformation with clones obtained from primary 
screening above. Growth of AIP1 as well as RASAL2-NPXY mutant is abrogated. SYNGAP 
and RASAL2 show strong interaction phenotype on the same selection plate used as above. 
0.2% 5FOA is a negative selection plate and shows a complementary growth pattern (Shin, 
D. unpublished data). 
The RASAL2 proteins contain a NPXY motif which binds the phosphotyrosine 
binding (PTB) domain of several proteins83. CCM2 contains a PTB domain so we 
wanted to determine whether this interaction specificity depended upon NPXY-
PTB binding. The interaction between CCM2 and RASAL2 disappeared when the 
amino acid residue asparagines (N783) on the NPXY domain of RASAL2 was 
mutagenized to histidine (Fig 5b) . 
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Nuclear CCM1 and CCM2 translocate to cytoplasm in response to stress 
CCMl and CCM2 have potential nuclear localization signal sequences. Based 
upon PSORTII software analysis, we found that CeMl has two putative nuclear 
No stimulus 
TNFa(10ng/ml) 
Figure 6. Nuclear CCM1 and CCM2 translocate to the cytoplasm following TNFo: treatment in N2A cells. As predicted 
by the PSORTII program, CeM1 protein overexpressed in N2A (a) shows a predominant nuclear localization , while 
CCM2 is overexpressed equally in both cytoplasm and the nucleus (b) . When the cells were treated with TNFct for 15 
minutes, nuclear CeM1 as well as CCM2 proteins no longer remain nuclear, but translocate to the cytoplasm (c,d). 
While arrows in c and d indicate the unoccupied nuclei after TNfa treatment. (Shin, D. unpublished data). 
localization signals: KKKRKK (46-51) and KKHK (569-572). According to this 
analysis the CCMl protein has a 69% chance of being found in the nucleus. 
CCM2 has one nuclear localization signal, RHRR (387-390) with a 52% chance 
of finding CCM2 in the nucleus. 
To determine the subcellular localization of CCMl and CCM2, mouse N2A cells 
were transfected with GFP-tagged constructs containing each protein after TNFa 
or sorbitol stimulation. CCMl was expressed mostly in the nucleus with weak 
cytoplasmic expression after over expression and in the absence of stimuli. 
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CCM2 was expressed equally in the cytoplasm and nucleus (Fig 6 a,b). The 
subcellular localization of CCM1 and CCM2 changed to mostly cytoplasmic after 
sorbitol or TNFa treatment for 15 minutes (Fig 6 c,d). CCM3 was localized to 





Fig 7. CCM3 [1 :500] antibody was used 10 stain Western blots 01 protein lysate extracted from 
homogeni~ed mouse tissue. Staining detected a protein of the fI)(Jl9CtOO band size (43kDa) for CCM3 In brain (AI 
blJl not In the Mgative control aortic tlssue(B). 
Characterization of CCM3 antibody 
Antibody specificity was determined for CCM3 by comparison of protein Iysates 
from homogenized mouse aortic and brain tissue and stained with CCM3 
antibody. Western blot stained a protein of expected band size of 43kDa (Fig 7). 
75- -
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Fig 8. CCM3 was expressed across all tissues except aorta using CCM3 antibody staining on 
Western blot of protein lysate from homogenized mouse tissue. The expected band size of 43kDa appeared 
Across all tissues except for the aorta. A. Heart B. Lung C,. Pancreas D. Liver E. Aorta F. Brain G. Muscle 
H. Spleen I. Kidney. Multiple bands were seen in brain, pancreatic and lung tissue. 
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CCM3 expression parallels CCM1 and CCM2 expression in mouse tissue 
In order to evaluate the pattern of CCM3 expression in different tissues Iysates of 
various mouse organs were analyzed by Western blot. Sections of human tissue 
from those organs which expressed CCM3 endogenously were stained with 
CCM3 antibody to analyze expression in human organs. Protein extracted from 
homogenized mouse tissue showed that CCM3 is expressed in lung, pancreas, 
brain , muscle, kidney, liver and heart but not in the aorta (Fig 8). 
Immunohistochemical staining of human tissue showed a similar pattern of 
expression with venous but not aortic CCM3 expression in the aorta (Fig 8). This 




Fig 4. Western blot analysis of MGC4607 expression in 12 human tissues. 
Bands are expected size of 2.4kb for CCM2. (Seker et al. Stroke. 2006;37:518.) 
CCM2 is expressed in brain , heart, spleen, skeletal muscle, thymus, kidney, liver, 
small intestines, placenta, lung, colon and peripheral blood leukocytes (Fig 4) . 
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CCM3 parallels CCM2 expression in Arterial Endothelial Cells 
The distribution pattern of CCM3 expression was determined by 
immunohistochemical staining of paraffin-embedded human tissue. CCM3 was 
Fig 9. Staining with CCM3-specific polyclonal antibody illustrates specific expression 
panern in cerebrovascular structures. CCM3 is expressed in arterial endothel ial cells 
in a similar pattern to CCM2 in a. medulla b. cerebellum c.lhalamus d.cortex. 
expressed in the perinuclear regions above the arterial endothelium in the 
medulla, cortex, cerebellum and thalamus (Fig 9). 
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Fig 10. CCM310calizes to various epithelia in the eXl racerebral organs. a. CCM3 is expressed in the splenic central arteries 
and some venous endothelium of the red pulp on the left. CCM3 is expressed in the arlerial endothelium of the white pulp of 
the spleen on the right. b. CCM3 is strongly expressed in the arterial endothelium lung but low expression 01 cytoplasmic or 
perinuclear staining c.There is low venous CCM3 expression in the aorta. d. CCM3ls expressed in the ductus and hepatocyte 
cytoplasm of the liver 
Extracerebral Tissue Expression 
Spleen: 
The CCM3 antibody is expressed in the central arterial endothelium but not in the 
venous endothelium in the white pulp but this pattem was not replicated in the 
red pulp of the spleen where CCM3 was expressed in some veins. On higher 
magnification CCM3 was shown to have nuclear expression in the spleen (Fig 
10a) . 
. Aorta: 
CCM3 was shown to be expressed in the endothelium or perinuclear region of 
the aorta (Fig 1 Ob). 
Lung: 
Lung tissue showed intense arterial endothelial CCM3 staining but venous 
endothelium had very low levels of expression (Fig 10c). 
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Liver: 
CCM3 was expressed in the ductus and hepatocyte cytoplasm of the liver but 
there was no venous endothelial staining (Fig 10d). 
Nuclear Renal Expression of CCM3 
Immunofluorescence of COS? renal cell line indicated nuclear CCM3 expression 
in the kidney. CCM3-HA tagged constructs were transfected into COS? cells. 
Cells transfected with CCM3-HA were incubated with Cy3, Dapi and gfp. A 
CCM1-GFP tagged construct was used as a positive control and nontransfected 
COS? cells were used as a negative control. The Dapi staining indicates that the 
Immunofluorescent staining was successful in that the majority of cells stained 
with CY3 also stained with the nuclear stain Dapi. Overlap of the Cy3 and Dapi 
shows significant nuclear expression of CCM3. CCM1 was previously known to 
have nuclear expression (data not shown). 
CCM3 interacts with SerinelThreonine Kinases 
The Y2H screen using CCM3/PDCD1 0 identified two members of the subfamily 
of STE20-like kinases: STK24 or Mst3, which was shown to phosphorylate 
p42MAPK, and STK25 or SOK-1, which is known to be induced by oxidative 
stress. CCM3 also interacted with KIAA0826 which is a homolog of the sensory 
axon guidance family member (sax-2) in C.elegans (Fig 11). These interactions 
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Fig 11. Identification of STK24, STK25, KlAA0826 as CCM3 binding partners. STK24,STK25, KlAA0826 in pGBKT7 
Clonlec/l bait vector which is -trp and CCM3 in pGADT7 prey vector which is --leu. The individual dones do not grow on 
the full drop oul plate bullhe mated constructs grow which indicates thai the complex activates the reporter gene. Controls 
are AH109, bait yeast strain, and YP187, prey yeast strain. 
against STK24, STK25 and KIAA0826 with identical yeast two hybrid technology 
by Invitrogen. The transformation was confirmed via westem blot and verified on 
appropriate dropout plates for self-activation. The prey and bait were then mated 
overnight at 300°C. Constructs were plated onto -Leu , -Trp, -Ade/Leurrrp, and -
His/Leurrrp/Ade (-HLTA) drop-out plates and incubated at 300°C for three to four 
days. Mated cultures were confirmed via PCR using gene specific primers and 
sent for sequencing to KECK to confirm that successful mating. 
Additional yeast-two hybrid done to verify interactions between STK24, STK25, 
and Kiaa0826. The - Trp plates yielded STK24, STK25, KIAA0826 colonies 
which corresponds to the pGBKT7 constructs where the vector is - Trp. This 
indicates activation of the reporter gene and confirms interaction between CCM3 
and these proteins. The CCM3 construct in the pGADT7 vector is -Leu and so 
did not yield colonies. The co-transformed plates with STK24 and CCM3, STK25 
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and CCM3 as well as KIAA0826 and CCM3 all yielded colonies indicating that 
the nonCCM3 colonies grew. The -Leu plates yielded CCM3 growth for the 
individual and co-transformed plates. The most stringent drop out plates -HL T A 
showed no growth for the individual constructs but yielded colonies for the 
cotransformed plates indicating the complex activates the reporter gene. The 
bait yeast strain AH109 served as a control to indicate there was no 
contamination of the single construct plates. 
Matched Reversed 
Fig 12. PCR amplification of bacterial STK25 in pGBKT7 and STK24 in pGBKT7 using matched and 
reverse primers. Amplification with the appropriate STK24 or STK25 primer yielded the expected band 
Of 1.3bp. The same colonies did not amplify using the primer set for the other STK protein. indicating that 
STK24 and STK25 are on different loci although they appear the same size and share significant overlap. 
Stk24 and Stk25 both produce a band at 1.3bp and KIAA0816 produces a band 
at 1.4bp. STK24 (13q31.2-q32.3) and STK25 (2q37.3) have a 73.7% overlap in 
408 amino acid residues. Since the serine threonine kinases produce bands of 
the same size and share significant homology we amplified colonies using 
matched and reverse primers to confirm that these two proteins were on 
separate loci. The colonies produced the appropriate size band when amplified 
with matched primers but did not when amplified with the opposite primer set (Fig 
12). 
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CCM Signaling Links Neural and Endothelial Elements 
Based on above data we constructed a hypothetical pathway in which CCM1 and 
CCM2 link the extracellular matrix to the cellular cytoskeleton and nucleus 
through integrin/Ras-MAPK signaling3 . Induction of apoptosis through these 
signaling cascades leads to CCM3 expression and cellular proliferation which are 
exhibited in the CCM pathology (Fig 13). 
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Fig 13. Interaction 01 CeM proteins leading 
to apoptosis. CeM! and CCM2 form a 
complex to activate the MAPK signaling 
cascade. CeM3 is a 10$s of function 
mutation triggered by apoptosis. This 
mutation leads to cell proliferation and 
CeM pathology. GeM1 mutations also 
undergo this direct morphogenesis after 
CCM1/1CAPl complexaclivates RAPIA. 








Cerebral cavemous malformations are caused by mutations in three known 
genes KRIT1, Malcaverinin (MGC4607), PDCD10, and possibly a fourth gene 
whose locus is close to PDCD10. Although mutations in the three distinct genes 
have been associated with CCMs they remain identical clinically and 
pathologically. 
The role of p38 MAPK signaling in CCM pathophysiology correlates with 
evidence that p38 MAPK signaling is induced by integrin activation and may 
regulate other cellular processes such as actin remodeling and apoptosis84.88 . 
Data showing that p38a null mice die early in gestation with significant placenta 
vascularization defects implicates the MAPK pathway in the regulation of 
angiogenesis89 . 
Our data indicates that CCM1 and CCM2 are necessary for the activation of 
stress-responsive mitogen activated signaling pathways p38 MAPK and JNK 
pathways through sorbitol and yeast two-hybrid assays. Further these two 
molecules appear to act as a complex to initiate the signaling cascade. Although 
CCM3 does not participate directly in these pathways yeast two hybrid data 
confirms direct interaction between CCM3 and STKswhich are implicated in 
MAPK signaling. This is also confirmed through si"RNA mediated gene silencing 
and overexpression studies. CCM1, CCM2 and CCM3 appear to be expressed in 
similar tissue distribution across the body although the CCM pathology is CNS 
43 
specific. In addition, the intracellular CCM expression is identical between CCM1 
and CCM2 and CCM3 is expressed in both the nucleus and cytoplasm, further 
supporting theories that CCM1 and CCM2 work as a complex that interacts with 
CCM3 to yield CCM pathology. 
Based on previous data we hypothesized that CCM1 and CCM2 but not CCM3 
were implicated in the same molecular genetic pathway responsible for 
communication between neural and glial elements in the CNS38 • Inflammatory 
states impact astrocytes as well as endothelial cells as studies have shown 
increased COgS-driven apoptosis in response to inflammation factors such as 
TNF-a, IL-1 ~ and INF-/o. Data presented here supports the theory that CCM1 
and CCM2 work as a complex to activate the stress-responsive p38 MAPK, JNK 
pathways and that CCM3 works independently in conjunction with the other 
proteins. The CCM1 and CCM2 proteins act as components of the MAPK 
cascade which activate CCM3 through apoptosis41 • Signaling pathways do not 
progress in a linear manner but act as multiple signaling pathways regulating one 
another to produce biological effects91 •93• 
We showed that CCM1 and CCM2 are endogenously coexpressed in COS? cells 
providing further evidence that these two proteins are involved in the same 
biochemical pathway (Fig 3). This is an important step towards elucidating the 
molecular signaling pathways responsible for CCM pathogenesis. Non-
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transfected cells pulled down with CCM1 or CCM2 but not the gfp antibody 
indicates that CCM1 and CCM2 are endogenously expressed. 
The theory that CCM1 and CCM2 act as a complex to initiate the p38MAPK 
cascade,41 is supported by the fact that the CCM1/CCM2 co-transfected cell 
Iysates pulled down with either the CCM1 and CCM2 antibody produces the 
corresponding band width. Previous data has shown this activation to be in 
response to osmotic stress. Our data confirms that CCM1 and CCM2 function via 
the p38 MAPK and c-Jun NH2-terminal kinase signaling pathways and are 
expressed as a complex in COS? cells. This supports previous data of a model 
where CCM signaling links the extracellular matrix to the cellular cytoskeleton 
and nucleus through integrin/Ras-MAPK signaling94. 
Evidence of siRNA mediated gene silencing and overexpression studies support 
this hypothesis (Table 1). Signal transduction of the integrin activated p38 MAPK 
signaling pathway may mediate cellular processes such as actin remodeling and 
cell apoptosis as well as vessel formation. The association between 
angiogenesis and MAPK cascade is suggested by the observation that p38a null 
mice are embryonic lethal and exhibit severe placental vascularization defects 89. 
Although the molecular function of CCM2is still being established, CCM2's 
mouse homolog, Osmosensing Scaffold for MEKK3 (OSM), has offered insight 
into CCM2 function and interaction with CCM1 . OSM has a phosphotyrosine 
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binding domain and is implicated in mechanosensing and osmosensing83. OSM 
regulates p38 MAPK signaling through direct interactions with MEKK3, Rac and 
actin83. The KRIT1 binding partner, ICAP10: inhibits Rac signaling, thus the Rac 
molecule may be a critical point of interaction between CCM1 and CCM237, 95. 96. 
Further, yeast two-hybrid data indicates that RasGAP proteins interact directly 
with CCM2 which supports the theory that this molecule is involved in the MAPK 
pathway and interacts directly with CCM1 to initiate involvement. 
The RasGAP proteins identified as CCM2 binding partners through yeast two-
hybrid assays are either predominately or exclusively expressed in the central 
nervous system (CNS)55. RasGAP proteins exhibit a spatial expression profile 
which may explain why CCM pathology is limited to the CNS although CCM 
expression is found throughout mammalian tissues (Fig 4; 8). One of the CCM2 
binding partners RASAL2 is a close family member to RASAL 1 which is mutated 
in hereditary capillary malformation-arterious malformation (CM-AVM). RASAL 1 
encodes p120 RasGAP which binds Rap1A which may be a binding partner of 
CCM1. 
Further studies have not supported this interaction possibly because there are 
two biologically active splice isoforms of CCM1 the other of which binds 
ICAP10:97. Clinically this is intriguing since CCMs ~ccasionally produce 
cutaneous lesions similar to those of CM-AVMs98. This evidence corroborates 
theories that CCM1 and CCM2are involved in the Ras-mediated MAPK signaling 
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pathway. Additional yeast two-hybrid data suggests that CCM3 may signal 
through the same pathways through interactions with serine threonine kinases 
which are upstream in the MAPK pathway. 
Yeast two-hybrid analysis of CCM2 also indicates that KIF5A interacts with 
CCM2. The isolation of this protein as directly interacting with CCM2 has 
interesting clinical implications and further supports theories that CCM1 and 
CCM2 work in concert. CCM1/KRIT1 knock-out mice have been shown to die 
early from closure of the dorsal aorta34• This supports histological data which 
shows CCM1 expression is restricted to arterial and microvascular endothelium 
with neurons and astrocytes99 • Another CNS specific condition, avintegrin 
mutants die from intracerebral hemorrhage early in gestation 100. Histological 
examination of these brains shows lesions which are phenotypically similar to 
CCMs. Conditional knock-out avintegrin mutants that survive exhibit hindlimb 
weakness which is similar to spastic paraplegia (SPG) which is a heterogeneous 
disease in humans 101.102. An autosomal dominant form of the disease, SPG1 0, 
is caused by mutations in kinesin 5A (KIF5A) gene which has been shown to 
interact with CCM2 101. This suggests an interaction between CCM signaling and 
av~8integrin which supports the theory that CCM signaling links neural elements 
with endothelial cells and is important in cerebrovascular development lOO. 
CCM1 and CCM2 have been shown to be necessary for activation of the stress-
responsive mitogen activated signaling pathways, p38 MAPK and JNK in 
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response to hyperosmotic shock (sorbitol) or TNFo: treatment. CCM1 has been 
shown to be a positive regulator of the p38 MAPK and JNK signaling pathways 
and CCM2 interacts with RasGAP proteins to initiate the MAPK cascade. 
Based upon these results we conclude that CCM signaling evokes a novel 
pathway allowing communication between neural and endothelial cells of the 
neurovasculature4o• When this pathway is disrupted by a mutation in a CCM 
protein , the normal CNS angiogenesis is altered and the changed communication 
between neural and endothelial cells results in the CCM pathology. CCM1 , 
CCM2 and CCM3 show similar patterns of expression in structures critical to the 
blood brain barrier. 
We showed that CCM3 is expressed across all tissues studied including the 
brain , heart and kidney (Fig 8-10) . Although protein lysate from homogenized 
mouse tissue did not appear to express CCM3 on repeated antibody staining on 
Western blot, the presence of CCM3 venous expression on 
immunohistochemical staining of human aortic tissue suggests its presence in 
the aorta (Fig 8). This correlates with previous data on CCM1 and CCM2 
expression (Fig 4) as well as current theories on CCM pathology and arterial 
morphogenesis103. The similar pattern of expression between CCM2 and CCM3 
across various extracerebral tissues supports theories that these two proteins 
may work through the same mechanism or signaling pathway in yielding the 
CCM pathology. 
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Unlike CCM2 protein expression, CCM3 appeared to be predominately 
expressed in the cytoplasm in the medulla. CCM3 was expressed in the purkinje 
cells of the cerebellum as well as glial cells in the molecular layer of the 
cerebellum (Fig 9). These glial cells form part of the membrane encapsulating the 
vessels which establishes the blood-brain barrier35. Thus mutations in CCM 
proteins in these cells may be responsible for the phenotypic leaky blood-brain 
barrier associated with CCM pathology. 
CCM2 is expressed by endothelial cells, specifically arterial and microvascular 
endothelium in all tissues. In the brain CCM2 is also expressed in pyramidal cells 
and astrocytes. CCM2 expression has been seen in astrocytes with foot 
processes which terminate on c.erebral blood vessels. The glial membrane which 
encapsulates the vessel and creates the blood brain barrier is established by 
these foot processes35. CCM lesions lack astrocytic foot processes and tight 
adherence junctions between endothelial cells creating the appearance of an 
immature vessel104. These lesions may have a proliferating, non-adherent 
endothelium rich in fibronection and poor in laminin 105. 
Previous data from this lab has shown high levels of CCM1 and CCM2 
expression in arterial endothelium as well as microstructures important to the 
integrity of the blood brain barrier. CCM lesions are CNS specific and CCM1 
expression has been shown to be isolated to arterial and microvascular 
endothelium of neurons and astrocytes including foot processes. This is 
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supported by the clinical phenotype of KRIT1 knock-out mice which die early due 
to closure of the dorsal aorta33, 34, To further support this hypothesis we found 
CCM3 shares a similar pattern of expression in mouse and human tissue which 
suggests that it is also implicated in normal angiogenesis and arterial 
morphogenesis, Data has shown this CCM protein to be important in 
cerberovascular development and remodeling43, CCM3 may also help regulate 
apoptosis in smooth muscle cells which is mediated by ~1-integrin signaling 
which interacts with CCM1 and CCM2 as we1l88, The interaction between KRIT1 
and ICAP1implicate CCM1 inthe ~1-integrin signaling pathway, 
CCM3 is important in cerebrovascular development and remodeling43, CCM3 is 
caused by mutations in PDCD1 0 which is a gene involved in the initiation of 
programmed cell death which is critical to arterial morphogenesis, Some 
evidence shows that apoptosis in smooth muscle cells is mediated by ~ 1-integrin 
signaling which interacts with CCM1 and CCM288 , Previous yeast two-hybrid 
analysis of KRIT1/1CAP1 indicate ~1-integrin signaling involvement in CCM 
pathophysiology36, 37, Our data confirms that CCM1 and CCM2 are positive 
regulators of p38 MAPK and JNK signaling pathways and that CCM3 expression 
is related to these pathways, 
In addition, CCM3 yeast two-hybrid data identified serine threonine kinases 
which are part of the STE20 family which is upstream of the MAPK cascade. This 
indicates that CCM3 may signal through the p38 MAPK cascade. Since CCM1 
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and GGM2 are implicated in the p38 MAPK and JNK signaling pathways, their 
activation of apoptosis may trigger GGM3. Another binding partner of GGM3, 
KIAA0826 is an osmold scaffolding protein which provides further evidence that 
the GGM proteins act in the communication between arterial and neuronal 
elements (Fig 11). 
Ste20-like kinases are a germinal center kinase that activate apoptosis through 
the p38 MAPK signaling cascade. Interestingly, Ste20 expression is increased in 
renal development and during the recover from acute ischemic renal failure. 
Overepxression of Ste20 has been documented during anoxia/recovery-induced 
apoptosis and is activated by homodimerization, signaling through ASK1 and p38 
to induce apoptosis 106. 
Further yeast two-hybrid assays are underway to find binding partners of STK24, 
STK25 and KIAA0826 in order to dissect the molecular signaling pathway 
responsible for GGM3 action. 
These findings offer greater insight into the understanding of GGM pathology. We 
suggest a model where GGM signaling links the extracellular matrix to the cellular 
cytoskeleton and nucleus through integrin/Ras-MAPK signaling (Fig 13). 
Identification of the signaling pathway(s) in which the GGM genes participate will 
not only provide insight into the molecular mechanisms underlying cerebral 
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angiogenesis and eeM pathology, but may also lead to new therapeutic 
approaches. 
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